This is not the latest version of this item. The latest version can be found here.
Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
Name
nihms-1527961.pdf
Description
Accepted version
Size
1.31 MB
Format
Adobe PDF
Checksum (MD5)
b4784708ab38d1708f48f50ad70b6c42
Author(s)
Abramson, Alex
Halperin, Florencia
Kim, Jane
Traverso, Giovanni
Date Issued
2019
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Citation
Abramson, Alex, Halperin, Florencia, Kim, Jane and Traverso, Giovanni. 2019. "Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide." Journal of Pharmaceutical Sciences, 108 (9).
Version
Author's final manuscript
Abstract
© 2019 American Pharmacists Association® Oral semaglutide, which has undergone multiple phase 3 clinical trials, represents the first oral biologic medication for type 2 diabetes in the form of a daily capsule. It provides similar efficacy compared with its weekly injection counterpart, but it demands a dose on the order of 100 times as high and requires more frequent administration. We perform a cost effectiveness analysis using a first and second order Monte Carlo simulation to estimate quality-adjusted life expectancies associated with an oral daily capsule, oral weekly capsule, daily injection, and weekly injection of semaglutide. We conclude that the additional costs incurred to produce extra semaglutide for the oral formulation are cost effective, given the greater quality of life experienced when taking a capsule over a weekly injection. We also demonstrate that the potency of semaglutide allows the formulation to be cost effective, and less potent drugs will require increased oral bioavailability to make a cost effective oral formulation.
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
10.1016/J.XPHS.2019.04.022
